1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

28 Mar 2024
Admin
News Article

Takeda Gains Approval for ADZYNMA® Intravenous Injection

Takeda Receives Approval for ADZYNMA® Intravenous Injection 1500 in Japan to Treat Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Overview

Takeda (TSE: 4502/NYSE:TAK) has announced the approval of ADZYNMA (apadamtase alfa/cinaxadamtase alfa) by the Japanese Ministry of Health, Labour and Welfare for treating congenital thrombotic thrombocytopenic purpura (cTTP) in individuals aged 12 and above. cTTP, an extremely rare clotting disorder, results from a deficiency in the ADAMTS13 enzyme and can lead to severe complications if left untreated, with mortality rates exceeding 90% for acute events.

Significance of ADZYNMA

Yasushi Kajii, Head of R&D Japan Region at Takeda, emphasized the significance of this approval, marking a crucial advancement for cTTP patients in Japan who previously had limited treatment options.
ADZYNMA, the first and only recombinant ADAMTS13 protein approved for cTTP, aims to address this unmet medical need by replacing the deficient enzyme.

Phase 3 Trial

The approval is based on comprehensive evidence from a Phase 3 trial (281102 NCT03393975), including data from Japanese patients, and is further supported by long-term safety and efficacy data from a continuation study (TAK-755-3002 NCT04683003).
Notably, during the study, no acute TTP events occurred in patients receiving ADZYNMA prophylactic treatment, contrasting with one event in patients receiving plasma-based therapies.

Adverse Events

Regarding safety, the incidence of treatment-related adverse events was significantly lower in the ADZYNMA group compared to those receiving plasma-based therapy, indicating a favorable safety profile for ADZYNMA. Moreover, Takeda stated that this approval doesn't alter its fiscal forecast for the year ending March 31, 2024 (FY2023).

Approval and Other Info

ADZYNMA, also approved by the U.S. FDA, offers both prophylactic and on-demand treatment options for cTTP patients, providing flexibility in managing this debilitating condition.
Its recommended dosage and administration have been outlined, catering to both prophylactic and acute treatment needs.

About CTTP

CTTP is a challenging condition associated with life-threatening complications and chronic symptoms. ADZYNMA's approval marks a significant step forward in addressing the unmet needs of cTTP patients, reflecting Takeda's commitment to advancing treatments for rare diseases.